Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

August 03, 2015 9:46 AM ET

Healthcare Equipment and Supplies

Company Overview of TYRX, Inc.

Company Overview

TYRX, Inc. manufactures and markets absorbable and non-absorbable antibacterial envelopes/implantable devices for cardiovascular, cosmetic surgical, and other pharmaceutical applications. The company offers its products to stabilize cardiac implantable devices; and reduce surgical site infection rates and treatment costs for high-risk patients. It serves customers worldwide. TYRX, Inc. was formerly known as TYRX Pharma, Inc. The company was founded in 1998 and is based in Monmouth Junction, New Jersey. As of December 30, 2013, TYRX, Inc. operates as a subsidiary of Medtronic plc.

1 Deer Park Drive

Suite G

Monmouth Junction, NJ 08852

United States

Founded in 1998





Key Executives for TYRX, Inc.

Chief Financial Officer
Chief Medical Officer
Age: 53
Vice President of Advanced Products
Vice President of Product Development
Compensation as of Fiscal Year 2015.

TYRX, Inc. Key Developments

TYRX, Inc. Announces First Implantation of AIGISRx R Fully Bioresorbable Antibacterial Envelope

TYRX, Inc. announced that the first implantation of its new AIGISRx R Fully Resorbable Antibacterial Envelope has taken place at the Vanderbilt Heart and Vascular Institute in Nashville, TN by Dr. Christopher R. Ellis. The AIGISRx R Antibacterial Envelope received U.S Food and Drug Administration (FDA) clearance on May 20, 2013. The AIGISRx R device is a fully bioresorbable, antibacterial mesh envelope, intended to hold Cardiac Implantable Electronic Devices (CIEDs), such as pacemakers and implantable cardioverter defibrillators (ICDs) securely in place to provide a stable environment when implanted in the body. The AIGISRx R contains the antimicrobial agents rifampin and minocycline, which are released locally into the tissue to help reduce Surgical Site Infections (SSIs) associated with CIED implantation. Multiple studies have shown that patients at high risk for CIED infection who are implanted with the AIGISRx Antibacterial Envelope had 70% to 100% fewer device infections than similar patients who did who did not receive the AIGISRx. Vanderbilt Heart and Vascular Institute recently performed a matched cohort study to compare the incidence of CIED infection in patients receiving a CIED with or without an AIGISRx Antibacterial Envelope. After a minimum of 90days of follow-up, the incidence of CIED infection was significantly lower in the group that received the AIGISRx, compared to those that did not (0.4% vs. 3.0%, OR = 0.13 [0.02-0.95],p=0.04). There were 87% fewer CIED infections in patients who received the AIGISRx, compared to those who did not.

Similar Private Companies By Industry

Company Name Region
Connective Orthopaedics, Inc. United States
Roxwood Medical, Inc. United States
Carwild Corporation United States
Perry Baromedical Corporation United States
Heartstream, Inc. United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact TYRX, Inc., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at